A1C

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Health, Regeneration, Learning, Glycated hemoglobin, Menin, C-peptide, Insulin, Diabetes, AUC, Patient, Fasting, MD, Metformin, Person, Cancer, Safety, A1C, DSM-IV codes, Pharmaceutical industry

REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced initial response data from the first two type 1 diabetes patients treated with BMF-219 in the ongoing Phase II study (COVALENT-112).

Key Points: 
  • “We are very excited to announce the initial response data from the first two type 1 diabetes patients enrolled in the COVALENT-112 study.
  • Both patients showed improvement in measures of beta-cell function after only 4 weeks of dosing with BMF-219.
  • The trial includes an open label portion for adults with type 1 diabetes up to 15 years since diagnosis.
  • It has been exciting to participate in this study and explore this new pathway for the benefit of our patients.

New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications

Retrieved on: 
Tuesday, March 12, 2024
Control, Single-frequency network, Conference, ATTD, Disease, Risk, Weight loss, Blood, Diabetes, Doctor of Philosophy, MD, Type 2 diabetes, Vaccination, A1C, BMI, Prediabetes, Medical device

NEW YORK, March 12, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today two new clinical studies presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) 2024, held March 6 – 9 in Florence, Italy.

Key Points: 
  • Dario's cardiometabolic solution integrates digital tools, connected devices and intelligent technologies to deliver a personalized and integrated experience to help drive better outcomes through effective behavior change.
  • Today, members can utilize the Dario solution with or without a GLP-1 medication and receive support tailored to their unique need.
  • The first study presented at ATTD analyzed the data of members engaged in Dario's cardiometabolic solution to manage pre-diabetes, a condition that requires weight loss and regulation of A1c.
  • A second Dario study presented at ATTD evaluated the effectiveness of Dario's digital health solution as a means to improve flu vaccine awareness and rates.

INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

Retrieved on: 
Monday, March 11, 2024
Diabetes, Senior, Randomized controlled trial, Inhalable insulin, RAA, Teaching, Hyperglycemia, MannKind Corporation, AUC, A1C, Standard of care, Conference, ATTD, Safety, University, MDI, Patient, Insulin, Automation, Clinical trial, T1D, Pharmaceutical industry

INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care.

Key Points: 
  • INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care.
  • “In this large, randomized trial utilizing more appropriate dose conversion, we are excited to see meal challenge results support the safety and efficacy of inhaled insulin from the start.”
    INHALE-3 is a 17-week randomized controlled trial with a 13-week extension.
  • Subjects utilizing inhaled insulin received a higher initial conversion dose than in the current label.
  • For the meal challenge, the inhaled insulin group took an inhaled insulin dose immediately prior to a standardized meal (a 240 calorie nutritional shake) whereas those using usual care used RAA 5-15 minutes prior to the meal.

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Friday, March 8, 2024
Molecule, Therapy, IPF, SAN, Research, Investment, Obesity, Apelin, Idiopathic pulmonary fibrosis, Growth, GIPR, GIP, A1C, Interim, Safety, GPCR, G&A, Glycated hemoglobin, Pharmaceutical industry

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent corporate achievements.

Key Points: 
  • “In 2023 we demonstrated clear proof-of-concept with our lead GLP-1 receptor agonist, GSBR-1290, for obesity and type 2 diabetes.
  • This study is fully enrolled and data are expected in the latter half of the second quarter of 2024.
  • The Company plans to initiate a global Phase 2b obesity study of GSBR-1290 in the fourth quarter of 2024.
  • Net Loss: Net loss for the fourth quarter of 2023 totaled $24.5, with non-cash stock-based compensation expense of $2.1 million, compared to $11.9 million for the fourth quarter of 2022 with non-cash stock-based compensation expense of $0.6 million.

MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8

Retrieved on: 
Tuesday, March 5, 2024
Senior, Randomized controlled trial, RAA, Teaching, EST, Diabetes, MannKind Corporation, ABC, A1C, Standard of care, Conference, ATTD, University, MDI, Patient, Insulin, Automation, Clinical trial, T1D, Pharmaceutical industry

INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care.

Key Points: 
  • INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care.
  • “With ABC and this trial, we used a higher initial conversion dose for inhaled insulin than in our current label.
  • In the ABC study, this conversion dose produced significantly lowered post-prandial glucose levels that peaked 30 minutes sooner than standard of care.
  • More information on the study is available at: ClinicalTrials.gov(NCT05904743) .

Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers

Retrieved on: 
Tuesday, March 5, 2024
Technology, Diabetes, Health, Apps, Applications, Pharmaceutical, Mental Health, Telemedicine, Virtual Medicine, Medical Devices, Software, General Health, Health Technology, Fitness & Nutrition, Clinical Trials, Cardiology, T2D, Nutrition, Randomized controlled trial, Education, Conditional sentence, Obesity, FDA, Food, White House conference, CHC, Federally Qualified Health Center, A1C, Conference, ACLM, Better, Therapy, Type 2 diabetes, American College, Food and Drug Administration, Patient, NTI, RCT, Medicine, Society, Harvard Medical School, Community health center, Prescription, FQHC, Partnership, Pharmaceutical industry

Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.S. Food and Drug Administration (FDA)-authorized product, AspyreRx , available to support underserved patients through 1,400 Federally Qualified Health Center (FQHC) organizations.

Key Points: 
  • Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.S. Food and Drug Administration (FDA)-authorized product, AspyreRx , available to support underserved patients through 1,400 Federally Qualified Health Center (FQHC) organizations.
  • This underscores the urgent need for evidence-based interventions to ensure equitable access to high-quality care for all.
  • The Lifestyle Medicine National Training Initiative (NTI) is an extension of ACLM’s $24.1 million commitment to the 2022 White House Conference on Hunger, Health, and Nutrition .
  • Better Therapeutics and ACLM are seeking additional partners and funding to support the implementation and maximize the initiative’s impact.

Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter

Retrieved on: 
Tuesday, March 5, 2024
Software, Health, FDA, Diabetes, Medical Devices, Health Technology, Wearables, Mobile Technology, Technology, CGM, Continuity, Multimedia, MD, DXCM, A1C, Type 2 diabetes, Stelo, Type 2, Smartphone, Insulin, Glucose, Insurance, Dietary supplement

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription.

Key Points: 
  • DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription.
  • There are approximately 25 million people in the U.S. living with Type 2 diabetes who do not use insulin and who can benefit from continuous glucose monitoring (CGM) technology.
  • Today, Dexcom G7 is available for them with a prescription.
  • To learn more about Stelo and do a benefits check to see if you’re eligible to get started now with Dexcom G7, visit https://www.dexcom.com/en-us/stelo .

Perry Health Named to the New York Digital Health 100 by Digital Health New York (DHNY)

Retrieved on: 
Wednesday, February 21, 2024
Diabetes, Health, Exercise, Digital, A1C, Nursing, Patient, Conditional sentence, Partnership

NEW YORK, Feb. 21, 2024 /PRNewswire/ -- Perry Health has been honored to be named in the 2024 New York Digital Health 100 ( DH100 ), a distinction that showcases the top digital health startups in New York.

Key Points: 
  • NEW YORK, Feb. 21, 2024 /PRNewswire/ -- Perry Health has been honored to be named in the 2024 New York Digital Health 100 ( DH100 ), a distinction that showcases the top digital health startups in New York.
  • The annual list is published by Digital Health New York ( DHNY ) in partnership with the New York Healthcare Innovation Report, providing valuable insights into investment trends, opportunities, and challenges within the digital health sector.
  • Perry Health, built on principles of inclusivity and equitable healthcare access, advocates for timely, personalized care for every patient, irrespective of their location or socioeconomic status.
  • "We're thrilled to be named to the New York Digital Health 100," stated Pan Chaudhury, CEO of Perry Health.

Best Life Insurance Plans for Diabetics - Our Top Picks for 2024

Retrieved on: 
Monday, February 12, 2024
A1C, Database, Lincoln National Corporation, Legal & General, History, ICC, Diagnosis, Diabetes, American Diabetes Association, Insulin, Pancreas, Mutual, CDC, Immune system, Anxiety, Woman, AEGON, Corebridge Financial, Prediabetes, Life expectancy, Insulin resistance, John Hancock Financial, Research, Insurance, SBLI, Roger Hawkins (drummer), MD, Prudential Financial, Cell, EKG, Policy, Privacy, Pharmaceutical industry

Continued Bland, "Our 50-insurer database is continually updated, which makes it a valuable resource for diabetics who are searching for the best buys in life insurance."

Key Points: 
  • Continued Bland, "Our 50-insurer database is continually updated, which makes it a valuable resource for diabetics who are searching for the best buys in life insurance."
  • Instant life insurance quotes for both type 1 and type 2 diabetics are available at www.lifequotes.com .
  • Life insurance policies described, quoted, shown and illustrated throughout this press release may not be available in all states.
  • Pacific Life Insurance Company of Newport Beach, CA, policy form P16LYT or ICC 16 P16LYT.

What do your blood test results mean? A toxicologist explains the basics of how to interpret them

Retrieved on: 
Tuesday, February 6, 2024
Glycated hemoglobin, Thyroid, BMP, Physical examination, Disorder, Hypothyroidism, Cell, BUN, Immune system, History, RBC, Heart, Blood urea nitrogen, Diabetes, Biomarker, Blood, Patient, Kidney, Triiodothyronine, Temperature, HB, TSH, Anemia, Nutrient, A1C, Disease, Thyroid hormones, Brain, Hematocrit, Fatigue, Waste, Health, HCT, Hormone, Plasma, Woman, Medical imaging

As part of my work, I rely on various health-related biomarkers, many of which are measured using conventional blood tests.

Key Points: 
  • As part of my work, I rely on various health-related biomarkers, many of which are measured using conventional blood tests.
  • Understanding what common blood tests are intended to measure can help you better interpret the results.
  • If you have results from a recent blood test handy, please follow along.

Normal blood test ranges

  • This range is essentially the upper and lower limits within which most healthy people’s test results are expected to fall.
  • To determine how your test results compare with the normal range, you need to check the reference interval listed on your lab report.
  • If you have results for a given test from different labs, your clinician will likely focus on test trends relative to their reference intervals and not the numerical results themselves.

Interpreting your blood test results

  • There are numerous blood panels intended to test specific aspects of your health.
  • These include panels that look at the cellular components of your blood, biomarkers of kidney and liver function, and many more.
  • This results from either lower than normal levels of red blood cells or a decrease in the quantity or quality of hemoglobin, the protein that allows these cells to transport oxygen.
  • A complete blood count panel measures various components of the blood to provide a comprehensive overview of the cells that make it up.
  • Low values of red blood cell count, or RBC, hemoglobin, or Hb, and hematocrit, or HCT, would indicate that the patient is suffering from anemia.
  • Providing additional information is the basic metabolic panel, or BMP, which measures the amount various substances in your blood.


With results from each of these panels, the health professional would assess the patient’s values relative to their reference intervals and determine which condition they most likely have. Understanding the purpose of blood tests and how to interpret them can help patients partner with their health care providers and become more informed about their health.
Brad Reisfeld does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.